Niagen Bioscience, Inc.
NAGENASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $212.86M
- P/E (TTM)
- 13.31
- Forward P/E
- 15.12
- Dividend yield
- -
- 52-week range
- $2.51$7.95
- Volume (live)
- -
- Avg. volume (3M)
- 505.20K
Niagen Bioscience (NAGE) Stock Price & Financial Analysis
Niagen Bioscience Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.46 - $2.59 |
|---|---|
| 52-Week High | $7.95 |
| 52-Week Low | $2.51 |
| Open | $2.58 |
| Volume (last close) | 555.78K |
| Average Volume (3M) | 505.20K |
| Revenue (TTM) | 129.08M |
|---|---|
| Net Income (TTM) | 15.99M |
| Free Cash Flow (TTM) | 5.67M |
| EPS (TTM) | $0.19 |
| Profit Margin | 12.39% |
| Operating Margin | 6.67% |
| Return on Equity (ROE) | 19.38% |
| Debt to Equity | 0.03 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 212.86M |
|---|---|
| Shares Outstanding | 82.50M |
| P/E Ratio (TTM) | 13.31 |
| Forward P/E | 15.12 |
| Price to Sales (P/S) | 1.65 |
| Price to Book (P/B) | 2.58 |
| EV/EBITDA | 8.21 |
| 50-Day MA | $3.00 |
|---|---|
| 200-Day MA | $4.16 |
| 1-Year Change | −64.80% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Niagen Bioscience at a Glance
As of the Oct 16, 2026 close, Niagen Bioscience (NAGE) has a market capitalization of $212.86M. The stock trades at 13.3× trailing earnings, 15.1× forward earnings and 1.6× sales. Over the trailing twelve months it earned $15.99M on revenue of $129.08M (a 12.4% profit margin) and generated $5.67M of free cash flow. Revenue grew 11.0% year over year.
As of its latest reported balance sheet, it holds $66.74M in cash and securities against $2.33M of debt, a net cash position of $64.41M.
Niagen Bioscience does not currently pay a dividend.
The share price is down 64.8% over the past year. At $2.49 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $2.51 to $7.95, below its 200-day moving average of $4.16.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $10.50, 321.7% above the Oct 16, 2026 close.
Frequently Asked Questions About Niagen Bioscience
What is the current stock price for NAGE?
As of the Oct 16, 2026 close, NAGE stock trades at $2.49. The 52-week range is $2.51–$7.95, with a day range of $2.46–$2.59.
What is the P/E ratio for NAGE?
As of the Oct 16, 2026 close, Niagen Bioscience's trailing twelve-month (TTM) P/E ratio is 13.3, meaning investors pay $13.3 for every $1 of annual earnings. The forward P/E is 15.1, reflecting analyst expectations for future earnings. Niagen Bioscience operates in the Healthcare sector.
Does NAGE pay dividends?
Niagen Bioscience does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for NAGE?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for NAGE is Buy. The average 12-month price target is $10.50, a 321.7% upside from the Oct 16, 2026 close of $2.49.
What is the market cap of NAGE?
As of the Oct 16, 2026 close, Niagen Bioscience's market capitalization is $205.4M, classifying it as a micro-cap company. Niagen Bioscience operates in the Healthcare sector within the Biotechnology industry.